0000899243-16-016569.txt : 20160324 0000899243-16-016569.hdr.sgml : 20160324 20160324205208 ACCESSION NUMBER: 0000899243-16-016569 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160322 FILED AS OF DATE: 20160324 DATE AS OF CHANGE: 20160324 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INOTEK PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 91 HARTWELL AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-676-2100 MAIL ADDRESS: STREET 1: 91 HARTWELL AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baumgartner Rudolph CENTRAL INDEX KEY: 0001632878 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36829 FILM NUMBER: 161528529 MAIL ADDRESS: STREET 1: C/O INOTEK PHARMACEUTICALS CORPORATION STREET 2: 131 HARTWELL AVENUE, SUITE 105 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-03-22 0 0001281895 INOTEK PHARMACEUTICALS CORP ITEK 0001632878 Baumgartner Rudolph C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE, 2ND FLOOR LEXINGTON MA 02421 0 1 0 0 See Remarks Stock Options (Right to Buy) 7.56 2016-03-22 4 A 0 165000 0.00 A 2026-03-21 Common Stock 165000 165000 D The stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). 25% of the options granted shall vest on the one year anniversary of January 1, 2016 and 1/36th of the remaining option grant shall vest on each monthly anniversary thereafter, subject to continued service through such dates. As previously reported on June 26, 2015, the Reporting Person was granted a stock option award under the Plan. The total beneficially owned derivative securities following the grant inadvertently included securities of a separate class, and accordingly such previously inadvertently reported shares are now properly excluded. In addition, the Price of Derivative Security reported on the June 26, 2015 Form 4 was inadvertently reported as $5.03 when it should have properly been recorded as $0. Executive Vice President, Chief Medical Officer /s/ Dale Ritter, Attorney-in-Fact for Rudolph Baumgartner 2016-03-24